FindTrial
Sign In

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07634640
Enrollment
70
Registered
2026-06-09
Start date
2023-11-03
Completion date
2027-05-31
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure With Preserved Ejection Fraction (HFPEF)

Keywords

heart failure with preserved ejection fraction

Brief summary

Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours

Interventions

DRUGFerumoxytol infusion

Ferumoxytol infusion followed by cardiac MRI

Sponsors

University of Florida
Lead SponsorOTHER
American Heart Association
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* HFpEF

Exclusion criteria

* Renal insufficiency

Design outcomes

Primary

MeasureTime frame
detection of inflammation72 hours

Countries

United States

Contacts

CONTACTEllen C Keeley, MD, MS
ellen.keeley@medicine.ufl.edu800-265-0820
CONTACTVanessa H Scheuble
Vanessa.scheuble@medicine.ufl.edu800-555-0820
PRINCIPAL_INVESTIGATOREllen C Keeley, MD, MS

University of Florida

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026